Safety and Efficacy of Treatment with Sofosbuvir + GS-5816 ± Ribavirin for 8 or 12 Weeks in Treatment-Naïve Patients with Genotype 1−6 HCV Infection

Reported by Jules Levin

AASLD Boston Nov 8-11 2014

Tram T. Tran1, Timothy R. Morgan2 , Paul J. Thuluvath3, Kyle Etzkorn4,

Federico Hinestrosa5, Myron Tong6, John McNally7, Diana M. Brainard7,

Lingling Han7, Brian Doehle7, Erik Mogalian7, John G. McHutchison7,

Raymond T. Chung8, Gregory T. Everson9

1Cedars-Sinai Medical Center, Los Angeles, CA; 2VA Long Beach, Long Beach, CA; 3Mercy Medical Center, Baltimore, MD; 4Borland-Groover Clinic, Jacksonville, FL; 5Orlando Immunology Center, Orlando, FL; 6Huntington Medical Research Institutes, Pasadena, CA; 7Gilead Sciences, Inc., Foster

City, CA; 8Massachusetts General Hospital, Boston, MA; 9University of Colorado Denver, Aurora, CO